VESPER-4

• Research type

  Research Study

• Full title

  Evaluating The Efficacy And Safety Of MET097, A Fully-Biased, Ultra Long-Acting GLP-1RA In People With Overweight Or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)

• IRAS ID

  1013271

• Contact name

  Stephanie Ranck

• Contact email

  stephanie.ranck@metsera.com

• Sponsor organisation

  Metsera, Inc

• Clinicaltrials.gov Identifier

  NCT07311850

• Research summary

  This study will test a medication called MET097. MET097 is an investigational medication, because it has not been approved by any health authorities to treat any condition. Research is ongoing into how it works and how safe it is. MET097 is being tested to see if it can treat overweight and obesity. Excess body weight and obesity are important health concerns because they are linked to many chronic diseases that impact health and well-being. MET097 is similar to human glucagon-like peptide-1 (GLP-1), a hormone that helps you feel full, slows down digestion, and regulates blood sugar levels. This study will try to find out:
  -If MET097 works, meaning if MET097 can reduce body weight.
  -How safe MET097 is, by evaluating what side effects MET097 causes and how bad they are. We will monitor and measure side effects experienced by participants in the study.
  -What the body does to MET097 by studying how the body breaks down MET097, and how long MET097 stays in the body. One of the things we will measure is the concentration.

  This study will compare MET097 with a placebo (dummy substance that looks like MET097 without any active study drug). Participants may receive 1 of 3 different MET097 dosing arms or placebo. This is a double-blinded study, which means that neither the study staff nor the participants will know which treatment group they are in.
  The study medication will be in sterile solution form and will be given by subcutaneous (under the skin) injection with an injection pen in the abdomen (the belly button area).
  The duration of the participation in this study will be approximately 98 weeks including the Screening period (3 weeks), treatment period (84 weeks) and post-treatment follow-up (11 weeks.)
  Approximately 3501 adult male or female participants, ≥18 years of age with obesity or overweight, will be included in this research study.

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  26/NW/0009

• Date of REC Opinion

  20 Feb 2026

• REC opinion

  Further Information Favourable Opinion